Following the resolution of Eli Lilly’s tirzepatide shortage in October, the FDA has officially declared an end to the supply ...

Shortages of Ozempic and Wegovy that have been in place for more than two years have been resolved, as supplies of the ...

On Friday, shares of Hims&Hers Health Inc (NYSE:HIMS) dropped over 20% following an FDA announcement that the supply shortage of Novo Nordisk (NYSE:NVO)'s weight loss and diabetes drugs was ending.

The FDA said the shortage of Novo Nordisk's weight-loss drugs Wegovy and Ozempic is resolved. The move could limit cheaper ...

American doctors, who tracked over 37 million people, said the injections put users at higher risk of nonarteritic ischemic anterior optic neuropathy (NAION).

When celebrities reveal their experiences with newer weight-loss drugs, there are upsides and downsides for patients and ...

Investors could be overestimating the contribution of Hims & Hers' compounded GLP-1 medications to its top line. Read why I ...

American doctors, who tracked over 37 million people, said the injections put users at higher risk of nonarteritic ischemic ...

Two Omaha women lost more than 300 lbs. combined with injections of a GLP-1 drug, which are used increasingly for weight loss ...

Long-term investments in top tech, health, and consumer staples for stability, growth, and reliable returns. Read what ...

Compounded weight-loss medications, such as those promoted in the Hims & Hers Super Bowl commercial “Sick of the System,” aren’t approved by the FDA. © 2025 ...

Six percent of Americans have used Ozempic, Wegovy and similar drugs. They’re unwitting experimental subjects.